IGF-1 LR3
Muscle Support | Cellular Growth | Regeneration
NOTE: Peptide Affect is an educational resource only. The information provided on this website is intended for informational and research awareness purposes and is not a substitute for professional medical advice, diagnosis, or treatment.
IGF-1 LR3
IGF-1 LR3 is a modified version of the naturally occurring Insulin-Like Growth Factor 1, a protein involved in growth and repair. The “LR3” part stands for “Long Arg3,” which means this version is slightly altered to make it last longer in the body and be more effective in research applications. Scientists have been studying IGF-1 LR3 for how it may help promote muscle development, improve recovery from injury, and support tissue regeneration.
In simple terms, this peptide acts like a growth signal. It tells cells—especially muscle, nerve, and bone cells—to grow, repair, and stay healthy. Researchers have also looked at how it might help cells absorb nutrients more efficiently, making it a topic of interest in areas like physical recovery, anti-aging, and even neurological repair. All findings so far come from lab-based research models. Still, the science points to exciting possibilities in the field of regenerative support.
- Official Name: Insulin-Like Growth Factor 1 Long Arg3
- Classification: Synthetic IGF-1 analog
- CAS Number: 143045-27-6
- Molecular Formula: C₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉
- Molecular Weight: ~9,111 Da
- Purity: 98%
Researchers have explored IGF-1 LR3 in a variety of areas, including:
- Muscle Growth and Repair: Studied for how it may encourage muscle cells to grow and recover faster after injury or exercise.
- Tissue Regeneration: Explored for its potential to support recovery in skin, tendons, and other soft tissues.
- Cellular Nutrient Uptake: Investigated for its ability to help cells absorb nutrients like glucose and amino acids more efficiently, supporting energy and repair.
- Anti-Aging and Recovery Support: Examined in aging models to see if it helps counteract muscle loss and promote better recovery as the body gets older.
- Neurological Support: Researched for how it may assist with nerve healing and protection, particularly after injury.
Find more information on areas of study HERE.
Potential side effects may include:
- Low blood sugar (hypoglycemia): Because IGF-1 LR3 improves glucose uptake, it can sometimes lower blood sugar more than expected.
- Water retention or puffiness: Some subjects showed mild bloating or swelling, which may be linked to increased nutrient transport.
- Joint stiffness or muscle tightness: This was occasionally reported in research models where the peptide triggered rapid muscle repair.
- Unwanted tissue growth: In rare models, researchers observed that cells other than muscle—such as fat cells or connective tissue—also grew.
See more details on possible side effects HERE.
Discovery and Origins
IGF-1 LR3, short for Insulin-Like Growth Factor 1 Long Arg3, traces its roots back to the original discovery of IGF-1 in the 1950s and 60s. Researchers studying how growth hormone influenced tissue development noticed that its effects were not always direct. Instead, growth hormone appeared to trigger the release of another molecule in the liver, one that acted as a middleman for cellular growth. This molecule was eventually identified and named somatomedin C, later renamed IGF-1 due to its structural similarity to insulin.
IGF-1 became a hot topic in endocrinology throughout the 1970s and 80s. It was found to be a critical growth signal in the human body, responsible for triggering protein synthesis, increasing nutrient uptake in cells, and supporting the growth of muscles, bones, and nerves. But as researchers explored its therapeutic potential, they quickly ran into a problem: IGF-1 in its natural form broke down quickly in the body, limiting its usefulness in research or therapy.
To solve this, scientists began engineering modified versions of IGF-1 in the late 1980s and early 90s. These analogs were designed to last longer in the bloodstream and bind less tightly to natural binding proteins that would otherwise reduce their activity. One of the most successful modifications was IGF-1 LR3. By changing a single amino acid (replacing arginine at position 3) and adding 13 extra amino acids to the N-terminal, researchers created a peptide with a longer half-life, increased stability, and up to 3 times more potency than native IGF-1 in research models.
While studying the effects of growth hormone, researchers discovered a secondary molecule responsible for stimulating tissue growth. This molecule was named somatomedin C, later reclassified as Insulin-Like Growth Factor 1 due to its similarity in structure and function to insulin.
Scientists successfully isolated and sequenced the IGF-1 protein, allowing for deeper understanding of its structure. This breakthrough enabled researchers to begin exploring analog development to improve its stability and extend its effects in laboratory models.
The IGF-1 LR3 peptide was engineered to overcome the limitations of native IGF-1. By modifying the third amino acid (arginine substitution) and adding a 13-amino-acid extension, researchers developed a version that resisted degradation and bound less to inhibitory proteins. This allowed it to remain active longer in research settings.
Peptide synthesis companies began producing IGF-1 LR3 for laboratory research purposes, marking its entry into wider use. Since then, it has been studied in a wide range of models focused on muscle growth, wound repair, and regenerative therapies.
Research and Development
Throughout the 1990s and early 2000s, IGF-1 LR3 was studied in various academic and biotech research settings. It gained attention for its potential to enhance muscle growth, speed up recovery, and support healing in injury models. Some researchers also investigated how it might influence nerve regeneration and insulin sensitivity. Due to its powerful cellular effects, IGF-1 LR3 became a staple in research looking at muscle wasting, aging, and metabolic decline.
Over time, it also caught the eye of sports science and regenerative medicine researchers. While IGF-1 LR3 has never been approved for human use, it has remained a subject of ongoing interest for its unique ability to stimulate growth without directly involving testosterone or other anabolic steroids. In recent years, it has gained more attention in the peptide research community for its potential role in injury recovery protocols and combination peptide stacks aimed at maximizing performance and repair.
Today, IGF-1 LR3 remains one of the most studied IGF analogs in research settings. Its stability, potency, and broad biological activity continue to make it an area of interest in preclinical models investigating everything from muscle regeneration to neuroprotection.
Areas of Research
IGF-1 LR3 has been studied for its role in supporting growth, recovery, and regeneration in the body. While the research is still limited to lab-based and animal studies, the interest comes from how IGF-1 LR3 seems to act like a “growth switch,” signaling cells to repair, grow, and absorb nutrients more efficiently. Scientists have looked at it in areas like muscle development, injury healing, and even nerve protection, trying to understand how it could support the body’s ability to bounce back from stress or damage.
One of the most explored areas of IGF-1 LR3 research is how it affects muscle tissue. In the body, muscle fibers grow and strengthen when they are stressed—like after exercise or injury—by activating small helper cells called satellite cells. These are responsible for repairing and building new muscle tissue. IGF-1 LR3 appears to activate these satellite cells more effectively than natural IGF-1, and because it stays active longer in the body, the growth signal lasts longer too.
Researchers have used IGF-1 LR3 in models where muscle tissue was damaged or under stress, such as in burn injuries, post-surgery recovery, or muscle-wasting conditions. In these models, the peptide appeared to help accelerate muscle regrowth and improve overall recovery. This area of research could be valuable for future studies into injury rehab, athletic training recovery, and conditions that cause muscle degeneration.
IGF-1 LR3 has also been explored in studies focused on general tissue healing, including tendons, ligaments, and skin. These structures don’t heal as quickly as muscles because they have less blood flow and fewer regenerative cells. However, IGF-1 LR3 may help by speeding up cell division and encouraging the formation of new tissue.
In preclinical models, it has been tested for how it affects recovery from tendon tears, skin wounds, and ligament damage. Researchers are looking at whether it helps form stronger, more organized collagen—the protein that makes up most of our connective tissues. Some research has also paired IGF-1 LR3 with other peptides like BPC-157 or TB-500 to study possible synergistic effects on injury recovery.
IGF-1 LR3 has been studied for how it helps cells absorb and use nutrients like glucose (sugar) and amino acids (protein building blocks). This function is essential for recovery and growth because damaged or growing tissues need fuel. Think of IGF-1 LR3 as a signal that tells the body, "Hey, now is a good time to bring in the supplies." In this case, those supplies are nutrients needed for energy and rebuilding.
This area of research is especially interesting to scientists studying insulin sensitivity, athletic recovery, and metabolic health. By helping the body shuttle nutrients into cells more efficiently, IGF-1 LR3 may support faster recovery and reduce energy loss after workouts or injuries. Researchers are also looking at how it may improve the quality of lean mass gains while minimizing fat gain in calorie-controlled research models.
As people age, their natural levels of growth hormone and IGF-1 tend to decline, which can lead to muscle loss, slower recovery from injury, and decreased physical performance. Researchers have studied IGF-1 LR3 in animal models simulating age-related decline to see if it can help reverse some of these effects.
In these studies, IGF-1 LR3 has shown promise in improving strength, maintaining muscle mass, and speeding up wound healing in older subjects. There’s also interest in its ability to enhance vitality and functional performance in aging models. Although this area is still developing, it’s one of the reasons the peptide has caught the attention of longevity researchers looking for ways to support healthy aging.
While IGF-1 LR3 is mostly associated with muscle and tissue support, it has also been explored for its potential role in nerve health. Some studies have tested how it behaves in nerve injury models, especially peripheral nerves (outside the brain and spinal cord). IGF-1 receptors are found on nerve cells, and activating those receptors may encourage healing and regrowth.
In research settings, IGF-1 LR3 has been observed to support neuron survival, reduce inflammation around nerves, and possibly stimulate the regrowth of damaged nerve fibers. These effects are still being studied, but it’s a growing field of interest for conditions involving nerve damage, including diabetic neuropathy, post-surgical recovery, and traumatic injury.
Key Research Findings
In lab settings, IGF-1 LR3 has shown promising effects. Here are some of the top takeaways:
- Faster muscle growth: Studies suggest it may activate satellite cells, which are like building blocks for muscle tissue. This could help speed up muscle development and repair after workouts or injury.
- Better tissue recovery: In preclinical injury models, IGF-1 LR3 appeared to support quicker healing of tendons, skin, and soft tissues.
- Increased nutrient use: It has been observed to help cells pull in more amino acids and glucose, which are both essential for energy and recovery.
- Longer activity in the body: Compared to natural IGF-1, the LR3 version sticks around longer in the system, potentially making it more effective in research protocols aimed at sustained growth or repair.
- Possible nerve protection: Some early studies suggest it may help protect or regenerate nerves, although this area is still being explored.
Research Limitations
It’s important to remember that IGF-1 LR3 is still being studied in preclinical settings. Most research has been done in animal models or isolated cell cultures, not in large-scale human trials. There are no official dosing guidelines, and effects in humans are still not confirmed. What we know is based on what researchers have seen in the lab—not in clinical use. That means while the science is promising, it’s still early. More research is needed to fully understand how it works, how it should be used, and what long-term effects it may have.
Safety and Other Considerations
IGF-1 LR3 has shown some exciting potential in lab studies, especially in areas like muscle growth, recovery, and tissue repair. But like anything that affects the body’s growth systems, it comes with important considerations. Since IGF-1 LR3 is a powerful peptide and research is still in early stages, it’s critical to understand what effects have been observed, what side effects might occur, and how different people may respond differently. All current knowledge is based on preclinical research, so while findings are interesting, they shouldn’t be taken as medical advice or a green light for human use.
In lab and animal models, IGF-1 LR3 has shown several physiological effects. Some of the most common findings include:
- Increased lean muscle growth and improved muscle repair
- Enhanced nutrient delivery to cells, especially glucose and amino acids
- Faster recovery times after muscle or soft tissue injury
- Improved wound healing in skin and connective tissues
- Support for nerve regeneration in certain injury models
In some cases, researchers also noted increased energy levels, better performance in physical tasks, and improved overall tissue function. However, a few studies reported that too much IGF-1 LR3 may lead to unwanted growth in non-target tissues, particularly if used at high doses or over long periods.
While side effects have been limited in research models, a few possible issues have shown up depending on dosage and individual response. These include:
- Low blood sugar (hypoglycemia): Because IGF-1 LR3 improves glucose uptake, it can sometimes lower blood sugar more than expected. This may be avoided by dosing around meals or reducing the dose if symptoms like shakiness or fatigue occur.
- Water retention or puffiness: Some subjects showed mild bloating or swelling, which may be linked to increased nutrient transport. Staying well-hydrated and avoiding overly high doses may help lessen this effect.
- Joint stiffness or muscle tightness: This was occasionally reported in research models where the peptide triggered rapid muscle repair. Stretching and mobility exercises during use may help mitigate this.
- Unwanted tissue growth: In rare models, researchers observed that cells other than muscle—such as fat cells or connective tissue—also grew. This is why dosage and duration matter and why more studies are needed to determine long-term safety.
Not all research subjects responded the same way to IGF-1 LR3. Some showed strong effects at low doses, while others needed more exposure to see results. Factors that affected response included:
- Body size and composition: Larger or more muscular subjects responded more predictably than smaller ones.
- Baseline health: Subjects with poor metabolic health or chronic injury responded differently than healthy ones.
- Duration of use: Some studies showed diminishing returns over time, while others found a “sweet spot” after a few weeks.
- Dose size: Higher doses often led to stronger effects but also increased the risk of side effects. Lower, steady doses appeared safer in most models.
This kind of variation is why most research protocols test different doses, monitor reactions over time, and include rest periods between use cycles.
There are several situations where researchers noted that IGF-1 LR3 might not be appropriate, even in a controlled setting. Based on lab findings, those with the following conditions would likely be excluded from studies:
- Active cancer or tumor history: IGF-1 encourages cell growth, and researchers avoid using it in any model where abnormal cell growth is a risk.
- Severe insulin resistance or diabetes: Because IGF-1 affects blood sugar, it may interfere with insulin or glucose control.
- Pregnancy or developmental conditions: Research models avoid using growth-promoting peptides in subjects who are still developing or pregnant.
- Existing hormone imbalances: If the body already has abnormal levels of growth hormone or insulin, adding IGF-1 LR3 could complicate the situation.
Because this peptide is still being studied, more contraindications could come to light with future research. Right now, researchers focus on healthy adult models or those with specific injury or repair needs.
Peptide Combinations and Synergies
Peptide stacking is a common research strategy where multiple peptides are used together to see if they produce better results than one alone. The idea is to find combinations that complement each other—where one peptide supports muscle growth, another might reduce inflammation or speed up healing. With IGF-1 LR3, stacking has mostly been studied in recovery and performance settings, especially where researchers want to boost repair, preserve muscle, or improve nutrient absorption. Understanding which peptides pair well (and which don’t) can help guide better decisions in future research.
This combination is often used in research focused on accelerating recovery after soft tissue injuries or intense physical stress. IGF-1 LR3 promotes growth and cell regeneration, while BPC-157 supports healing by increasing blood flow, reducing inflammation, and protecting tissues at the cellular level.
Why it works: IGF-1 LR3 helps cells grow and repair, especially in muscle and connective tissues. BPC-157 complements this by creating the right environment for that repair to happen—calming inflammation and improving circulation to injured areas.
Common research goals:
- Post-surgical healing
- Sports injury recovery
- Muscle strain and joint pain recovery
- Improving strength and mobility after trauma
TB-500, a synthetic fragment of thymosin beta-4, is known for its role in cellular migration and tissue remodeling. When combined with IGF-1 LR3, the goal is full-spectrum repair—getting cells to the injury site and encouraging them to grow once they’re there.
Why it works: TB-500 helps cells move and organize in damaged tissue, especially in ligaments, tendons, and skin. IGF-1 LR3 provides the growth signal to rebuild that tissue stronger. The synergy here comes from timing: TB-500 sets the stage, IGF-1 LR3 brings the growth.
Common research goals:
- Ligament and tendon repair
- Chronic injury healing
- Full-body tissue regeneration after intense training
- Muscle growth with structural integrity
This stack is often used to explore how the body’s own growth hormone production can work in tandem with IGF-1 LR3’s downstream effects. CJC-1295 with Ipamorelin encourages the pituitary to release natural growth hormone, which then stimulates native IGF-1. Adding IGF-1 LR3 gives a more targeted and prolonged effect.
Why it works: CJC-1295 and Ipamorelin help regulate and boost GH in a pulsatile, natural pattern. IGF-1 LR3 provides a direct and sustained signal to grow and repair. Together, this mimics a natural, youth-like growth cycle.
Common research goals:
- Improving recovery and performance
- Supporting healthy aging and hormone balance
- Enhancing lean body mass
- Restoring natural growth hormone rhythms
Epitalon is often studied in aging models for its possible role in supporting telomere length, cell lifespan, and natural melatonin cycles. When paired with IGF-1 LR3, researchers aim to slow down aging while promoting healthy regeneration and repair.
Why it works: Epitalon may support the body’s long-term cell maintenance and circadian rhythm, while IGF-1 LR3 focuses on short-term tissue growth and repair. One works upstream on aging; the other downstream on physical function.
Common research goals:
- Anti-aging and longevity studies
- Cellular rejuvenation and mitochondrial health
- Improved sleep, energy, and regeneration in aging models
MOTS-c is a mitochondrial peptide that’s been researched for improving energy balance, glucose control, and fat metabolism. Paired with IGF-1 LR3, this stack supports muscle growth while encouraging the body to burn fat for fuel.
Why it works: IGF-1 LR3 helps build muscle and pull nutrients into cells. MOTS-c helps cells use those nutrients more efficiently by improving mitochondrial function and insulin sensitivity.
Common research goals:
- Body composition improvement
- Fat loss while preserving lean mass
- Support for metabolic stress or insulin resistance
- Enhanced physical performance in aging subjects
GHK-Cu is a copper-binding peptide that has been widely studied for its effects on skin healing, collagen synthesis, and hair follicle health. When stacked with IGF-1 LR3, the result is often improved structural repair in skin and connective tissue.
Why it works: IGF-1 LR3 promotes cellular repair and new tissue growth. GHK-Cu boosts collagen formation, skin remodeling, and anti-inflammatory effects. Together, they may enhance wound healing, reduce scarring, or support cosmetic recovery in research models.
Common research goals:
- Post-surgical or cosmetic recovery
- Hair restoration research
- Skin firmness and elasticity
- Improved collagen integrity
AOD-9604 is a modified fragment of human growth hormone studied for its ability to break down fat without the side effects of full hGH. Pairing it with IGF-1 LR3 may help preserve or even grow muscle while shifting the body’s focus toward fat metabolism.
Why it works: IGF-1 LR3 encourages lean tissue growth and helps muscles absorb nutrients. AOD-9604 signals the body to break down stored fat for energy, especially in hard-to-target areas like the abdomen.
Common research goals:
- Weight loss with lean muscle retention
- Recomposition strategies (fat loss, muscle gain)
- Fat metabolism support in metabolic disorder models
Combinations That May Interfere or Be Redundant
Not all peptide combinations provide synergistic benefits. Some may be redundant, meaning they target the same biological pathways, offering little additional benefit. Others may interfere with each other, potentially counteracting their effects or overloading regulatory systems in the body. Below are some combinations that may not be ideal for research purposes.
While both IGF-1 LR3 and native IGF-1 act on the same receptors, LR3 has been modified to last longer and bind less to binding proteins in the blood. This gives it more time to interact with IGF-1 receptors. Adding native IGF-1 on top of LR3 doesn’t improve results and may actually lead to receptor saturation. In some cases, the shorter half-life of native IGF-1 can interfere with the longer-acting LR3, blunting the overall effectiveness.
Why it may be redundant: Both peptides target the exact same mechanism. Using both doesn’t double the results but can overload the system.
When to avoid: In any protocol already using LR3, adding native IGF-1 offers little added value and may lead to insulin sensitivity issues or low blood sugar.
Insulin and IGF-1 share very similar signaling effects when it comes to glucose transport into cells. Both lower blood sugar and enhance nutrient absorption. When used together, they may exaggerate this effect, leading to an increased risk of hypoglycemia in research models. This combination also increases the complexity of managing nutrient timing and blood sugar balance.
Why it may be problematic: The two compounds share overlapping glucose-regulating actions, increasing the risk of instability.
When to avoid: In metabolic research or any situation involving insulin resistance, diabetes models, or fat-loss studies where blood sugar fluctuations are already a concern.
Growth hormone indirectly stimulates IGF-1 production in the liver. When large doses of GH are used along with IGF-1 LR3, the result may be too much stimulation of the same growth pathways. This could increase risks like water retention, joint pain, or tissue overgrowth. While small doses of GH secretagogues are often beneficial, stacking full-dose hGH and LR3 together may become counterproductive.
Why it may be redundant: Both lead to elevated IGF-1 activity. Combining them can push levels too high without increasing effectiveness.
When to avoid: In hypertrophy-focused stacks, especially when long-term use is involved or when side effects like puffiness and insulin resistance are already present.
Some stacks overload the GH axis by combining multiple peptides that all signal the pituitary to release growth hormone. Adding IGF-1 LR3 on top of that can create excessive feedback to the system, which may reduce the body's natural response over time. There’s also a risk of disrupting GH pulse rhythm, especially in longer protocols.
Why it may be problematic: Too much stimulation of the same hormonal system can lead to tolerance, resistance, or hormonal suppression.
When to avoid: When already using two or more GH secretagogues, adding LR3 should be done with caution and not at high doses. This is especially true in long cycles or anti-aging protocols.
Some experimental peptides or SARMs aim to mimic testosterone by boosting protein synthesis and nitrogen retention. These effects can overlap heavily with IGF-1 LR3’s cellular growth actions. When combined, they may promote unbalanced growth or stress the cardiovascular system, especially in research focused on muscle hypertrophy.
Why it may be redundant: Both drive muscle growth through similar end results—boosting protein uptake and muscle fiber size.
When to avoid: In muscle-building research, stacking too many growth stimulators can lead to systemic strain without additional benefit. If the goal is lean mass with minimal side effects, choose one central growth agent.
Some experimental stacks pair LR3 with high levels of synthetic androgens (testosterone or DHT derivatives). While the goal may be maximum growth, the risk is overstimulating growth pathways, which could contribute to unwanted tissue growth, fluid retention, or hormonal feedback issues.
Why it may be problematic: When growth hormone, IGF-1, and androgens are all dialed up, there’s less control over what grows—muscle, fat, connective tissue, or even abnormal cells.
When to avoid: In body composition or general health studies where balance and long-term safety are the goal. Overlapping growth signals may cause rapid size gains without proportional strength or stability.
While stacking IGF-1 LR3 with one metabolic enhancer can help support fat loss and muscle retention, using too many can send mixed messages to the body. Some peptides push for nutrient storage (like IGF-1 LR3), while others push for breakdown (like AOD-9604 or MOTS-c). This tug-of-war could result in inefficient outcomes or metabolic confusion in test subjects.
Why it may be problematic: Conflicting pathways can cancel each other out or increase stress on systems like the liver and pancreas.
When to avoid: In metabolic stacks with more than two targeted compounds. Prioritize synergy, not variety.
Co-Administration Findings in Research
In research models, how peptides are administered plays a big role in synergy. A few trends have emerged:
- Timing matters – IGF-1 LR3 is often given post-exercise or after tissue stress in studies to maximize muscle repair. When paired with healing peptides like BPC-157 or TB-500, staggered timing (morning vs evening) is sometimes used to maintain steady signals.
- Separate injection sites – Researchers sometimes use different locations for different peptides to reduce receptor competition or local irritation. For example, IGF-1 LR3 may be injected near a muscle group, while BPC-157 might be delivered near a joint or injury site.
- Lower doses, longer duration – Many stacked protocols use lower doses of each peptide spread over longer periods rather than maxing out single peptides. This helps avoid receptor burnout and keeps the cellular environment more balanced.
Mechanisms of Action in Combination Research
When peptides are combined in research, their pathways often overlap or reinforce one another. Here’s how IGF-1 LR3 fits into the bigger picture:
- Receptor activation – IGF-1 LR3 primarily activates IGF-1 receptors, which signal cells to grow and repair. Other peptides may target GH receptors, fibroblast receptors, or inflammatory markers. The goal is to create a multi-layered repair response.
- Cellular synergy – Peptides like BPC-157 help bring blood flow and reduce inflammation, while IGF-1 LR3 pushes cells to divide and grow. Together, this can speed up the rebuilding process after injury or stress.
- Nutrient optimization – IGF-1 LR3 improves how cells take in nutrients, especially protein and glucose. When combined with peptides that influence fat metabolism (like AOD-9604), the result may be better body composition and energy usage in research subjects.
- Balancing repair and regeneration – Stacks often aim to not just grow tissue, but grow the right tissue. For example, pairing GHK-Cu with IGF-1 LR3 may steer repair toward healthy collagen formation instead of just swelling or scar tissue buildup.
Dosing Guide: Research-Based Applications
IGF-1 LR3 is a long-acting growth peptide that has been widely studied in animal and lab-based models for muscle growth, tissue repair, and cellular recovery. Because it’s more stable than natural IGF-1, it’s usually dosed in smaller amounts and less frequently. Dosing isn’t one-size-fits-all—it depends on the research goal, the size of the test subject, and whether the goal is recovery, growth, or long-term support. While all current information is based on preclinical studies, there are clear patterns in how researchers have used this peptide effectively in various experiments.
Choosing the right dose of IGF-1 LR3 in a research setting depends on what outcome is being studied. In general, this peptide is effective at low doses due to its potency and long-lasting effect in the body. Here’s a breakdown of typical ranges and why someone might choose each one:
Low Dose (10 to 20 mcg per day)
This is considered a gentle range and is often used in longevity or wellness-focused research. The goal here isn’t rapid change but steady cellular support. Researchers looking at anti-aging, improved recovery without size gains, or metabolic balance may stay in this zone.
Why someone might use it: Supporting recovery from workouts without pushing growth too hard, interested in cellular repair or mild tissue support, or exploring anti-aging benefits in older research subjects
Moderate Dose (25 to 50 mcg per day)
This is the most commonly used range in muscle-building and repair studies. It tends to offer strong effects while staying within a tolerable and safe level for most subjects in controlled models. Researchers exploring performance, strength, or post-injury regrowth often choose this range.
Why someone might use it: Promoting lean muscle growth, supporting healing from a recent muscle strain, surgery, or injury, or enhancing recovery from regular intense training
High Dose (75 to 100 mcg per day)
These doses are typically used in short-term or acute injury models where rapid regeneration is the focus. While powerful, higher doses may increase the risk of side effects like low blood sugar or water retention if not carefully monitored.
Why someone might use it: Targeting recovery after major tissue trauma or surgery in a short time frame, trying to accelerate results in a controlled burst, or willing to cycle off sooner due to intensity of the dose
Important note: More isn’t always better. High doses may lead to faster changes, but they also require more caution and shorter durations. Researchers usually start at a moderate dose and adjust up or down based on response.
Due to its long half-life—often lasting up to 20 to 30 hours in research models—IGF-1 LR3 doesn’t require frequent dosing.
- Daily or every-other-day injections are common in studies focused on muscle growth or post-injury healing.
- Some protocols have explored 2 to 3 times per week, especially in long-term studies where steady exposure is the goal without overstimulation.
- In phased research, loading periods (daily use) are sometimes followed by maintenance phases with less frequent dosing.
Because it stays active for over a day, spacing out doses helps maintain effect while reducing stress on the system.
Timing can play a key role in how IGF-1 LR3 is used in research. Since this peptide helps transport nutrients into cells and stimulates tissue repair, the timing often aligns with periods when the body is primed to grow or recover.
- Post-workout: In studies involving exercise or physical strain, IGF-1 LR3 is typically administered shortly after activity to support muscle repair.
- Morning or early day use: This timing may reduce the chance of blood sugar dips during sleep, since IGF-1 can increase glucose uptake.
- Dosed with food or carbs: In metabolic studies, researchers sometimes pair dosing with meals (especially those containing carbs) to help stabilize blood sugar.
Overall, most findings suggest that post-exercise and fed-state dosing support the most efficient tissue recovery and nutrient absorption.
To avoid overstimulation or reduced responsiveness, some research protocols follow structured dosing cycles.
- Loading phase: Higher doses (e.g., 50 to 100 mcg daily) for 2 to 4 weeks.
- Maintenance phase: Lower doses (e.g., 25 mcg every other day) for 2 to 4 more weeks.
- Off-cycle: A break of 2 to 4 weeks to allow natural systems to reset.
This phased approach mimics how the body naturally regulates growth signals, giving time for receptors to recover and reducing the risk of long-term desensitization.
The length of time IGF-1 LR3 is used in studies varies based on the research goal. Because it influences growth and repair, it’s rarely used continuously without breaks. Instead, it’s structured in phases.
Short-Term Use (4 to 6 weeks)
This is the most common research duration, especially in recovery or rehab models. Subjects receive daily or frequent dosing to kickstart healing and then stop after noticeable progress.
When short-term makes sense: Recovering from injury, strain, or surgery; enhancing recovery during a training cycle; or exploring rapid response or tolerance testing
Mid-Length Use (8 to 12 weeks)
In more gradual or long-term studies, researchers keep subjects on IGF-1 LR3 for up to 3 months to observe changes in body composition, performance, or regeneration. The dose may taper over time to prevent overstimulation.
When mid-length makes sense: Supporting steady muscle growth or body recomposition; balancing recovery with physical performance over time; running a full “on-cycle” before taking a break
Off-Cycle or Break Periods (2 to 4 weeks off)
Most protocols recommend taking a break after a research cycle. This gives the body time to reset, prevents tolerance, and avoids potential negative feedback on hormone pathways.
Why breaks are important: Allows the body to maintain balance and avoid overstimulation; helps keep future dosing more effective; and reduces long-term strain on insulin and growth hormone systems
In general, cycle lengths of 4 to 12 weeks followed by a 2 to 4-week rest period are the most common and safest patterns seen in research.
Dosing Calculator
Peptide Dosing Calculator
Peptide Reconstitution Guide
Proper reconstitution is essential to achieve accurate concentrations for research applications. The amount of bacteriostatic (BAC) water added to the lyophilized peptide determines the solution’s concentration, which in turn affects the precision of dosing measurements.
Choosing the Right Reconstitution Volume
The amount of BAC water you add determines the final concentration of the solution, which affects how easy it is to measure doses.
- More water (higher dilution) = Easier to measure small doses, but larger injection volumes.
- Less water (lower dilution) = Smaller injection volumes, but sometimes harder to measure precise microdoses.
Common Reconstitution Ratios & Measurements
To make dosing easy to measure while keeping injection volume reasonable, here are some suggested reconstitution amounts for this peptide.
The following table outlines the volume (in units) corresponding to common research doses, based on the reconstitution options using a standard (orange) 1mL needle. Note: 1 unit on a 1mL insulin syringe equals 0.01mL.
NOTE: Measuring doses below 10 units (0.1mL) can be challenging due to the small volume. Conversely, doses above 30 units (0.3mL) may be uncomfortable due to the amount of liquid injected. Numbers in red indicate doses exceeding 50 units (0.5mL), which may not be recommended due to potential discomfort and injection site limitations.
Dosing Chart for 0.1mg Vial
With a 0.1mg vial, to keep the dosing volumes easily measurable, it’s recommended to reconstitute with the following considerations. Doses below 30mcg, measurements may be easier using 1mL BAC water. Doses above 30mcg may be most comfortable with 0.5mL BAC water or consider using a vial with a smaller mass concentration (i.e., 1mg).
Note: Reconstituting 0.5mL of bacteriostatic water in a 3mL peptide vial is common, but take caution. Though it can allow you to have more concentrated solutions for smaller doses, it can be more difficult to evenly mix. It’s possible to leave a portion of the peptide lyophilized powder on the vial walls, so ensure to mix thoroughly.
Turn your phone sidewards to view the entire table. The blue stars suggest recommended doses while the red caution signs represent high doses (which may not be recommended) based on the BAC water reconstitution.
For specific dosing not listed below, use the DOSING CALCULATOR above to determine the dose (in UNITS) to use.
Desired Does (mcg) | 0.5mL BAC Water | 1mL BAC Water |
|---|---|---|
10 mcg (0.01 mg) | 5 units | 10 units |
20 mcg (0.02 mg) | 10 units | 20 units |
30 mcg (0.03 mg) | 15 units | 30 units |
50 mcg (0.05 mg) | 25 units | 50 units |
75 mcg (0.075 mg) | 38 units | 75 units |
100 mcg (0.1 mg) | 50 units | 100 units |
Dosing Chart for 1mg Vial
With a 1mg vial, to keep the dosing volumes easily measurable, it’s recommended to reconstitute with the following considerations. Doses below 50mcg, measurements may be easier using 3mL BAC water or consider using a vial with a smaller mass concentration (i.e., 0.1mg). Doses above 50mcg may be most comfortable with 2mL BAC water.
Note: 3mL of bacteriostatic water in a 3mL peptide vial will bring the volume up to the neck of the bottle and has the potential to overflow. Also, there is very little air space left, which can make mixing more difficult. Be careful not to cause the vial to overflow. Be precise in your measurements.
Turn your phone sidewards to view the entire table. The blue stars suggest recommended doses while the red caution signs represent high doses (which may not be recommended) based on the BAC water reconstitution.
For specific dosing not listed below, use the DOSING CALCULATOR above to determine the dose (in UNITS) to use.
Desired Does (mcg) | 2mL BAC Water | 2.5mL BAC Water | 3mL BAC Water |
|---|---|---|---|
25 mcg (0.025 mg) | 5 units | 6 units | 8 units |
30 mcg (0.03 mg) | 6 units | 8 units | 9 units |
50 mcg (0.05 mg) | 10 units | 13 units | 15 units |
75 mcg (0.075 mg) | 15 units | 19 units | 23 units |
100 mcg (0.1 mg) | 20 units | 25 units | 30 units |
Step-by-Step Instructions for Reconstitution
For a more detailed step-by-step process on reconstituting your peptide, click HERE.
- Gather your supplies
- A vial of your peptide (e.g., 0.1 mg or 1 mg vial)
- Bacteriostatic water (BAC water)
- An insulin syringe (1 mL / 100 units)
- An alcohol swab
- A sterile mixing syringe (3cc syringe with a needle; 3cc = 3mL)
- Clean the vial tops
- Use an alcohol swab to clean the rubber tops of both the peptide vial and the BAC water vial.
- Draw up BAC water
- Using a 3cc sterile mixing syringe, pull in the desired amount of BAC water (see dilution chart below).
- Inject BAC water into the peptide vial
- Slowly inject the BAC water. When you put the needle in, it will automatically draw out the liquid from the syringe due to the vacuum seal.
- Let the peptide dissolve
- Do not shake the vial. Instead, gently swirl or roll it between your fingers until fully dissolved.
- Store properly
- Once reconstituted, store the vial in the refrigerator (36-46°F / 2-8°C) to maintain stability.
Understanding Syringes for Peptide Reconstitution and Dosing
When working with peptides, choosing the right syringe is essential for accurate dosing and comfortable injections. The two most commonly used syringes are:
- 3 mL (or 3cc) Syringe – Used for Reconstitution
- 1 mL (or 100-unit) Insulin Syringe – Used for Dosing and Injection (orange)
Measure BAC Water in mL for Reconstitution
Measured in "UNITS" for dosing injections
3 mL Syringe – For Mixing (Reconstitution) Only
- Why it’s used: The 3 mL syringe is best for drawing up BAC water and injecting it into the peptide vial. It allows you to accurately measure larger amounts of liquid (e.g., 1.5 mL, 2 mL, 2.5 mL) and inject it slowly and carefully into the peptide vial.
- Measures in milliliters (mL), with each marking usually representing 0.1 mL (10 units on an insulin syringe).
- Typically comes with a removable needle, which is helpful when transferring liquid into the peptide vial.
- Not ideal for measuring small doses of peptides, as the markings are too large for precise measurements.
1 mL Insulin Syringe – For Measuring and Injecting Peptides
- Why it’s used: Once the peptide is reconstituted, the 1 mL insulin syringe is used to draw and administer doses accurately.
- Measures in “units” rather than mL (100 units = 1 mL).
- Smaller increments allow for more precise dosing—each tiny line represents 1 unit (0.01 mL).
- Comes with a fixed, ultra-thin needle, which is ideal for small-volume subcutaneous injections.
- Helps keep doses accurate and injection volume low, making it the preferred choice for research applications.
How to Use Each Syringe in the Reconstitution Process
Step 1: Reconstituting the Peptide (Using the 3 mL Syringe)
- Draw up the desired amount of BAC water using a 3 mL syringe.
- Slowly inject the BAC water into the peptide vial, directing the liquid against the inner wall of the vial rather than directly onto the powder.
- Allow the powder to dissolve naturally. Do not shake—gently swirl the vial until fully mixed.
Step 2: Measuring the Dose (Using the 1 mL Insulin Syringe)
- Once the peptide is fully dissolved, switch to the 1 mL insulin syringe (orange) for accurate dosing.
- Pull the plunger back to draw in air equal to the dose you need, then inject the air into the peptide vial to equalize pressure.
- Slowly draw out the required dose, matching the units on the syringe with the reconstituted concentration (see dosing chart below).
- Make sure no air bubbles remain in the syringe before injecting.